1. Home
  2. FINW vs IPHA Comparison

FINW vs IPHA Comparison

Compare FINW & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FinWise Bancorp

FINW

FinWise Bancorp

N/A

Current Price

$13.85

Market Cap

194.1M

Sector

Finance

ML Signal

N/A

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$2.01

Market Cap

165.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FINW
IPHA
Founded
1999
1999
Country
United States
France
Employees
198
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
194.1M
165.3M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
FINW
IPHA
Price
$13.85
$2.01
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
20.2K
184.0K
Earning Date
04-30-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
21.51
N/A
EPS
0.35
N/A
Revenue
N/A
N/A
Revenue This Year
$160.48
$180.36
Revenue Next Year
$35.27
N/A
P/E Ratio
$39.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.82
$1.18
52 Week High
$22.49
$2.71

Technical Indicators

Market Signals
Indicator
FINW
IPHA
Relative Strength Index (RSI) 46.44 46.64
Support Level $13.72 $1.67
Resistance Level $14.62 $2.29
Average True Range (ATR) 0.39 0.08
MACD -0.00 -0.03
Stochastic Oscillator 46.53 6.67

Price Performance

Historical Comparison
FINW
IPHA

About FINW FinWise Bancorp

FinWise Bancorp is an independent bank that provides a full range of banking services to individual and commercial customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: